BIOA B Stock Overview
Develops biological drugs for patients with disorders of the central nervous system in Sweden.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIOA B from our risk checks.
BioArctic AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 224.80 |
52 Week High | SEK 337.40 |
52 Week Low | SEK 175.00 |
Beta | -0.15 |
11 Month Change | -9.14% |
3 Month Change | 6.84% |
1 Year Change | -25.02% |
33 Year Change | 53.97% |
5 Year Change | 212.22% |
Change since IPO | 675.17% |
Recent News & Updates
Recent updates
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth
Dec 05BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate
Sep 15BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business
Aug 23Is BioArctic AB (publ) (STO:BIOA B) Trading At A 41% Discount?
Jun 03Shareholders Will Probably Not Have Any Issues With BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation
Apr 29Shareholder Returns
BIOA B | SE Biotechs | SE Market | |
---|---|---|---|
7D | 0.8% | -1.7% | 0.6% |
1Y | -25.0% | 11.0% | 14.3% |
Return vs Industry: BIOA B underperformed the Swedish Biotechs industry which returned 16.4% over the past year.
Return vs Market: BIOA B underperformed the Swedish Market which returned 14.1% over the past year.
Price Volatility
BIOA B volatility | |
---|---|
BIOA B Average Weekly Movement | 7.9% |
Biotechs Industry Average Movement | 8.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.4% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: BIOA B has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOA B's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 90 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain.
BioArctic AB (publ) Fundamentals Summary
BIOA B fundamental statistics | |
---|---|
Market cap | SEK 19.86b |
Earnings (TTM) | -SEK 122.17m |
Revenue (TTM) | SEK 252.21m |
78.7x
P/S Ratio-162.5x
P/E RatioIs BIOA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOA B income statement (TTM) | |
---|---|
Revenue | SEK 252.21m |
Cost of Revenue | SEK 77.90m |
Gross Profit | SEK 174.31m |
Other Expenses | SEK 296.48m |
Earnings | -SEK 122.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | -1.38 |
Gross Margin | 69.11% |
Net Profit Margin | -48.44% |
Debt/Equity Ratio | 0% |
How did BIOA B perform over the long term?
See historical performance and comparison